Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime
Recruiting
Sir Salimullah Medical College Mitford Hospital
Phase 2
2023-11-01
This open level randomized controlled trial will be conducted in the department of medicine
at Sir Salimullah Medical College and Mitford Hospital. Clinical severity will be assessed by
the POP (Peradeniya Organophosphorus Poisoning) scale of admitted patients having a history
of organophosphorus poisoning within 24 hours with clinical features and physical evidence of
poisoning consumed. Only moderate severity (POP Scale score 4-7) of OPC (Organophosphorus
compound) patients will be included in this study. Then one group of patients will be treated
with atropine and pralidoxime and another group will be treated with atropine. The outcome
will be noted as clinical improvement or recovery. hospital stay, requirement of ICU, death.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
